Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

In the second episode of The Deep End, listeners hear what it’s like to live with severe depression and the backstory of an experimental treatment.

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...

We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with ...

The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is ...

A new non-invasive treatment for depression, which has been shown to deliver remission for one third of its patients, is to ...